Development
Ocular Therapeutix, Inc.
OCUL
$8.23
-$0.105-1.26%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 13.50% | 16.07% | 9.39% | 4.69% | 18.32% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.50% | 16.07% | 9.39% | 4.69% | 18.32% |
| Cost of Revenue | 14.37% | 10.81% | 9.47% | 4.37% | 6.45% |
| Gross Profit | -21.28% | 24.48% | -10.07% | -2.32% | 40.65% |
| SG&A Expenses | 3.25% | 8.82% | 11.68% | 11.11% | 7.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.20% | 9.71% | 10.69% | 8.03% | 7.07% |
| Operating Income | -4.74% | -5.63% | -11.55% | -10.22% | -0.79% |
| Income Before Tax | -13.65% | -12.99% | -179.16% | -299.77% | -984.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.65% | -12.99% | -179.16% | -299.77% | -984.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.65% | -12.99% | -179.16% | -299.77% | -984.05% |
| EBIT | -4.74% | -5.63% | -11.55% | -10.22% | -0.79% |
| EBITDA | -3.73% | -5.35% | -12.09% | -10.95% | -1.23% |
| EPS Basic | -9.25% | -12.00% | -176.93% | -297.21% | -978.06% |
| Normalized Basic EPS | -28.61% | -35.16% | -177.02% | -297.46% | -979.25% |
| EPS Diluted | -23.05% | -13.59% | -29.83% | -27.07% | -7.19% |
| Normalized Diluted EPS | -33.41% | -37.41% | -193.32% | -313.64% | -959.23% |
| Average Basic Shares Outstanding | 3.82% | 1.54% | 0.89% | 0.62% | 0.63% |
| Average Diluted Shares Outstanding | 0.06% | -0.32% | -5.31% | -3.84% | -3.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |